Knee Reconstruction
Nov 22, 2023
Innovative Pathways in Joint Reconstruction: Market Dynamics and Future Horizons
In recent years, the joint reconstruction devices market within the realm of orthopedics has undergone a profound evolution, owing to the technological advancements and innovations that have revolutionized treatment modalities and patient outcomes to a much greater extent. The intersection of innovative technologie...
Read More...
Apr 27, 2023
GE HealthCare’s CARESCAPE Canvas Patient Monitoring Platform; Medtronic’s MiniMed™ 780G System; Nevro Enroll’s First Patient in PDN Sensory Study; Syntr Health Presents Data from Facial Fat Transfer Clinical Study; Devyser-Thermo Fisher Scientific Signs Agreement; Smith+Nephew Introduced Digital Tensioning Device
GE HealthCare’s CARESCAPE Canvas Patient Monitoring Platform Received FDA Clearance On April 20, 2023, GE HealthCare, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, received the US FDA 510(k) clearance for its CARESCAPE Canvas patient monitoring platform f...
Read More...
Nov 24, 2022
Mainstay Medical’s ReActiv8-C Study; Swing Therapeutics Announced Results from Studies of Stanza; FDA Approves Empatica’s Health Monitoring Platform; FDA Clearance to Persona OsseoTi Keel Tibia System; ClariPi Joins Siemens Healthineers Digital Marketplace; Sony Launches Cloud-based Solution for Flow Cytometry Data Analysis
Mainstay Medical Published Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study On November 22, 2022, Mainstay Medical, a medical devices company, announced that the data from the ReActiv8®-C study, a single-centre, real-world study with a one-year clinical follow-up of selected patients, is publ...
Read More...
Jun 30, 2022
LumiThera’s US LIGHTSITE III Trial; First Patient Enrolled in Vascular Closure Device Study of Teleflex; Varian’s Flash Technology Clinical Trial, FAST-02; 3Spine’s MOTUS Device; Illumina’s Research Test to Detect Tumor Genome; Acutus Medical’s AcQCross Qx System
LumiThera Announced the Result of US LIGHTSITE III Trial of Non-neovascular Age-Related Macular Degeneration (AMD) Subjects Treated with Photobiomodulation (PBM) using the Valeda® Light Delivery System On June 22, 2022, LumiThera Inc., a commercial-stage medical device company offering photobiomodulation (PBM) t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
